FindTrial
Sign In

Durvalumab (MEDI4736)

DRUG8 trials

Sponsors

AstraZeneca, European Organisation for Research and Treatment of Cancer - EORTC, Memorial Sloan Kettering Cancer Center, Assistance Publique Hopitaux De Marseille, Radboud University Medical Center

Conditions

Colorectal CancerLiver MetastasesNon Small Cell Lung Cancer NSCLCNon Small Cell Lung Carcinoma NSCLCNon-muscle-invasive Bladder CancerNon-small Cell Lung CancerRectal CancerThyroid Cancer

Early Phase 1

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Active, not recruitingNCT03215095
Memorial Sloan Kettering Cancer CenterThyroid Cancer
Start: 2017-07-10End: 2026-07-31Updated: 2025-07-17

Phase 2

Synergism of Immunomodulation and Tumor Ablation
CompletedNCT03101475
European Organisation for Research and Treatment of Cancer - EORTCColorectal Cancer, Liver Metastases
Start: 2018-11-23End: 2022-02-23Updated: 2022-05-31
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
Active, not recruitingNCT03833440
Assistance Publique Hopitaux De MarseilleNon-small Cell Lung Cancer
Start: 2019-10-08End: 2025-02-28Updated: 2024-05-03
Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer
CompletedNCT03853187
Radboud University Medical CenterNon-small Cell Lung Cancer
Start: 2019-09-19End: 2022-12-06Updated: 2022-12-07
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer
NCT04293419
Grupo Espanol Multidisciplinario del Cancer DigestivoRectal Cancer
Start: 2019-12-18End: 2025-03-01Target: 58Updated: 2021-06-21
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
RecruitingNCT06680050
Mario Negri Institute for Pharmacological ResearchNon Small Cell Lung Cancer NSCLC
Start: 2025-08-07End: 2029-01-31Target: 21Updated: 2025-12-18

Phase 3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Active, not recruitingNCT03003962
AstraZenecaNon Small Cell Lung Carcinoma NSCLC
Start: 2017-01-02End: 2026-06-30Updated: 2026-03-11
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Active, not recruitingNCT03528694
AstraZenecaNon-muscle-invasive Bladder Cancer
Start: 2018-05-14End: 2028-10-03Updated: 2025-11-25

Related Papers

Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
2025-10-174 citations
The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami?
2025-08-051 citations
Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.
2025-07-12
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
2024-11-071 citations
[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
2021-04-015 citations
Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers.
Journal of Clinical Oncology2020-05-203 citations
A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
Journal of Clinical Oncology2019-03-0119 citations